Neoadjuvant chemoimmunotherapy is associated with significantly improved survival outcomes compared with standard ...

"The findings uncover a new way in which the immune system is suppressed, limiting T cells from fighting cancer spread. This ...

Mutant KRAS in ctDNA in patients with localized pancreatic cancer was shown to be a biomarker for metastatic progression and ...

Despite the high incidence of brain metastasis after resection of non-small cell lung cancer (NSCLC), the National Comprehensive Cancer Network guidelines do not recommend central nervous system (CNS) ...

A federally funded research team led by Sheri Holmen, PhD, investigator at Huntsman Cancer Institute and professor in the ...

Citizens JMP analyst Jonathan Wolleben lowered the firm’s price target on Aura Biosciences (AURA) to $19 from $21 and keeps an Outperform ...

(the "Company") announced that the Company has received a clinical trial notice approving the investigational new drug application for a radionuclide-drug conjugate (RDC) drug SKB107 (formerly TBM-001 ...

The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...

The FDA has approved Gozellix (kit for the preparation of gallium Ga 68 gozetotide injection) for use in patients with prostate cancer.

While the US attempts to stop it from spreading, the EU enters stage 4 metastasis.

Neuroendocrine tumors that start in the pancreas tend to be more aggressive and have a poor prognosis.

The following is a summary of "Early prediction of progression-free survival of patients with locally advanced nasopharyngeal ...